The Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis (PRISMS) was a double-blind, placebo-controlled trial of interferon beta-1a in patients with relapsing-remitting multiple sclerosis.
Patients had mild to moderate multiple sclerosis (EDSS scores 0 - 5.0).
Patients were randomised to 2 years of:
- 22 mcg subcutaneously three times per week
- 44 mcg subcutaneously three times pre week
- 1) PRISMS Study Group. (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet, 352(7), 1498-504
Last reviewed 01/2018